KolmarBNH콜마비앤에이치
200130 · KOSDAQ · ₩200130 · 콜마비앤에이치
- Market cap
- ₩208B
- Enterprise value
- ₩240B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 1.0%
- ROE
- −0.4%
- Net margin
- −0.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.3% from the high
₩7,220Today: ₩7,220 – ₩7,490₩15,150
Returns
- 1W−8.0%
- 1M−5.6%
- 3M−12.3%
- 6M−37.9%
- YTD−43.6%
- 1Y−49.2%
- Volume today
- 80,086
- 2.4× the 20-day average
- Traded today
- ₩583M
- Listed shares
- 28,775,558
- EPS (12 months)
- −₩54
- Earnings yield −0.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Warming up- BuzzRisingBuzz 59: heavy trading.
- SentimentMixedNews: The filings are listed by title only, so no clear positive or negative tone can be read. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-5.9% over the last month; the price is below its 20-day average.
- News impactHigh3 news items and filings in two weeks; 2 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
KolmarBNH stock overview
KolmarBNH (콜마비앤에이치, KRX: 200130) is listed on KOSDAQ, in the Biotech & Pharma sector. This Korean company develops core ingredients for health functional foods and cosmetics, using natural-product-based materials to make ODM/OEM health functional foods and cosmetics that it produces and sells. Its shares closed at ₩7,220 on Oct 27, 2026, down 0.96% on the day, giving it a market value of ₩208B.
Key facts
- Market cap
- ₩208B
- Sector
- Biotech & Pharma
- Latest price change
- −0.96%
- As of
- Oct 27, 2026
- Main business
- This Korean company develops core ingredients for health functional foods and cosmetics, using natural-product-based materials to make ODM/OEM health functional foods and cosmetics that it produces and sells.
Quick answers about KolmarBNH
- What does KolmarBNH do?
- This Korean company develops core ingredients for health functional foods and cosmetics, using natural-product-based materials to make ODM/OEM health functional foods and cosmetics that it produces and sells. Its consolidated 2025 revenue was split mainly between health functional foods (about 55%) and cosmetics (about 42%), with the rest from oral care and hygiene products and rental/other income. It operates production and R&D sites in Sejong, Eumseong, Incheon and Seoul in Korea, and has subsidiaries in China (Jiangsu, Shandong) and Australia (Sydney), exporting to 26 countries, with China, the United States, Taiwan, Russia and Japan as major export markets.
- What is the market cap of KolmarBNH?
- The market capitalisation of KolmarBNH was ₩208B at the close on Oct 27, 2026.
- Who are the largest shareholders of KolmarBNH?
- According to the latest official filings, the largest reported holders are Colmar Holdings (54.84%, as of Sep 30, 2026); National Pension Service (0.34%, as of Dec 31, 2025); WisdomTree Emerging Markets SmallCap Dividend Fund (0.14%, as of Jun 30, 2026).
- When is the next earnings report from KolmarBNH?
- Korean companies rarely announce results dates in advance. Based on when KolmarBNH filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own KolmarBNH?
- Yes. The National Pension Service held 0.34% of KolmarBNH shares as of Dec 31, 2025.
Company profile
This Korean company develops core ingredients for health functional foods and cosmetics, using natural-product-based materials to make ODM/OEM health functional foods and cosmetics that it produces and sells. Its consolidated 2025 revenue was split mainly between health functional foods (about 55%) and cosmetics (about 42%), with the rest from oral care and hygiene products and rental/other income. It operates production and R&D sites in Sejong, Eumseong, Incheon and Seoul in Korea, and has subsidiaries in China (Jiangsu, Shandong) and Australia (Sydney), exporting to 26 countries, with China, the United States, Taiwan, Russia and Japan as major export markets.
Written by AI from the company's latest annual report.
- Korean name
- 콜마비앤에이치
- Sector
- Biotech & Pharma
- Themes
- K-beauty
- Business group
- Kolmar
- CEO
- 이승화
- Founded
- Apr 2014
- Listed
- Jul 2014
- Listed shares
- 28,775,558
- Fiscal year ends
- Month 12
- Website
- www.kolmarbnh.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Determination of Shareholder Register Closure Period or Record DateOct 28, 2026
- Merger decisionOct 28, 2026
- Merger decisionOct 28, 2026
- 5%+ holding reportSep 30, 2026
- Amended: Acquisition of shares in another companySep 2, 2026
Titles in Korean until English translations are added.
Also known as: KolmarBNH / 콜마비앤에이치 / 200130 / KRX:200130
Source: KRX statistical information